-continued

```
ttaaaagagg tgagcaaaca cacccccagg tgatgtgtga ggctgggatg attgttctaa    420

agtcagttga gggcattcga gggatcagga ggagctcgaa gaattaagca aaggaaagca    480

cgattctact ctgggatgtg cacagatggt cacctcttat ccccagtcta gtcctccgca    540

gcccttcctg ttttaaaaga gggaaaaccc cgaggacgcc tggagctatg gaggaaggaa    600

ggaggcagaa tctgaggaag gggcgcggat ctgggctggg aagccagcag gcggccactt    660

agggcgtagc agaccaaaga ggaggccagt tctgcctgcg taccggtact ctcgctctca    720

tccgggtact gcgacctctg gcggttagga gaaggcggga cctcaggggg cggggcctcg    780

cttggttggc cgcctcgggc tccgtaagtc ctccaagagg ccaggtgagg ccgtcccgtg    840

atcctctgcg cctggcctct ctggcctgca acgtgtctca ggggcggagg cagcagccac    900

ggagttggct gcgtgagggt gggggttctc agtctcttcg ctcgcgcccg tctctctatc    960

gtcgctctag gcgccccacg ggccaaccca aggcctcaat atg                     1003


<210> SEQ ID NO 12
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 12

atggaggctg tctgatgaag cct                                             23


<210> SEQ ID NO 13
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 13

gctcctcctg atccctcgaa tgc                                             23
```

What is claimed is:

1. A method for alleviating a symptom of degenerative muscular diseases, comprising:

administering a therapeutically effective dose of stem cells or progenitor cells transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins by an intramuscular route to damaged muscle cells of a subject in need thereof,

wherein the symptom is weakness of muscles.

2. The method of claim **1**, wherein the HN and F proteins are derived from sendai virus, human immunodeficiency virus 1, influenza virus or vesicular stomatitis virus.

3. The method of claim **1**, wherein the vector is any one selected from the group consisting of a linear DNA plasmid DNA, a non-viral recombinant vector, a viral recombinant vector, and an inducible gene expression vector system.

4. The method of claim **3**, wherein the viral recombinant vector is any one selected from the group consisting of retroviruses, adenoviruses, adeno-associated viruses, helper-dependent adenoviruses, herpes simplex viruses, lentivirus vectors, and vaccinia viruses.

5. The method of claim **1**, wherein the degenerative muscular diseases are selected from the group consisting of myopathy, congenital myopathy, congenital muscular dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, Limb Girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular atrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, myotonic dystrophy, Barth syndrome, heart failure, and X-linked dilated cardiomyopathy.

6. The method of claim **1**, wherein the stem cells or progenitor cells are autologous, allogenic, or xenogenic cells.

7. The method of claim **1**, wherein the stem cells are embryonic stem cells, adult stem cells, or induced pluripotent stem cells.

* * * * *